FAQs


Can one participate if one has sequencing performed elsewhere? 
As with prior successful consortia, we would hope that this serves as a catalyst for a data sharing, processing and analysis activity that goes far beyond that supported by this study. We will expect to invest in importing and reprocessing data from other projects external to the Broad Institute (providing those data back to contributors and keeping it for mega-analyses described above) and also for potentially developing ways of integrating site and allele count information from processed studies that cannot engage in data sharing at the same level.

Is microbiome/metagenome sequencing available? 
While this current funding opportunity does not support microbiome sequencing, this is available at the Broad Institute and we would enthusiastically support projects that propose both exome and microbiome studies from the same individual should support for the microbiome component be available elsewhere. We encourage contacting Ramnik Xavier for information about microbiome sequencing available at the Broad Institute. Current studies focus on microbiome analysis of diagnostic gut biopsy samples, and longitudinal fecal samples collected across a period of disease perturbation (treatment, diet, disease flares, etc). The Broad institute is committed developing and defining best practices for research and interpretation of studies involving the human microbiome.

Can additional sequencing at the same low exome price be available to partners with their own funding support? 
CSGs and other IBD partners with their own sources of support for expanding their studies or performing related studies not directly supported by HIESP funding will be able to develop further projects using the same exome sequencing capabilities at the low price point available to HIESP (the current subsidized price at Broad is at or below $500/exome available for non-NIH funding sources). These data (raw and identically processed) would be provided back directly to the group, though it would be our fervent hope that such data, if relevant or even to extend control numbers, would be available for the joint mega-analyses in IBD.